• Bio-Works secured a SEK 2.8 million order from a global US biotechnology customer developing mRNA-based medicines and vaccines.
• Contract covers use of Bio-Works purification products and expertise in development of a drug candidate for next-generation medicine.
• Project scope could expand if the customer advances the program toward manufacturing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Works Technologies AB published the original content used to generate this news brief via Cision (Ref. ID: 20260820:BIT:0001:0) on August 25, 2026, and is solely responsible for the information contained therein.